share_log

NuCana | 20-F: FY2024 Annual Report

SEC ·  Mar 20 20:30

Summary by Moomoo AI

NuCana plc, a clinical-stage biopharmaceutical company, reported improved financial results for FY2024, with net losses decreasing to £19.0 million from £27.6 million in 2023. The company's cash position stood at £6.7 million as of December 31, 2024, down from £17.2 million the previous year. Share-based payment expenses decreased significantly to £1.6 million from £3.9 million YoY.The company continues to advance its pipeline, with NUC-7738 in Phase 2 trials for solid tumors and melanoma, and NUC-3373 progressing through Phase 1b/2 trials for solid tumors and lung cancer. Management has implemented cost control measures, reflected in reduced key management compensation from £6.0 million to £3.6 million in 2024.Looking ahead, NuCana has initiated strategic financial moves, including a post-period ATM program raising £0.5 million through ADS issuance. The company plans a share restructuring in April 2025, involving the subdivision of 151,923,897 ordinary shares. Risk management remains focused on currency exposure, interest rates, and credit risk, with over 99% of cash held in A-rated institutions.
NuCana plc, a clinical-stage biopharmaceutical company, reported improved financial results for FY2024, with net losses decreasing to £19.0 million from £27.6 million in 2023. The company's cash position stood at £6.7 million as of December 31, 2024, down from £17.2 million the previous year. Share-based payment expenses decreased significantly to £1.6 million from £3.9 million YoY.The company continues to advance its pipeline, with NUC-7738 in Phase 2 trials for solid tumors and melanoma, and NUC-3373 progressing through Phase 1b/2 trials for solid tumors and lung cancer. Management has implemented cost control measures, reflected in reduced key management compensation from £6.0 million to £3.6 million in 2024.Looking ahead, NuCana has initiated strategic financial moves, including a post-period ATM program raising £0.5 million through ADS issuance. The company plans a share restructuring in April 2025, involving the subdivision of 151,923,897 ordinary shares. Risk management remains focused on currency exposure, interest rates, and credit risk, with over 99% of cash held in A-rated institutions.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Doc 5

Doc 6

Doc 7

Doc 8

Doc 9

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 247

Recommended

Related Stocks Related Stocks
Symbol Mini Chart Price
Portage Biotech
PRTG
9.600
Lexicon Pharmaceuticals
LXRX
0.571
DBV Technologies
DBVT
6.200
NeOnc Technologies
NTHI
16.550
Alumis
ALMS
5.640
Log In for the Full List
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina Show More
Can strong earnings reports drive Chinese concept stocks to continue rising?
77%
23%
Bullish
Bearish
1532 votes
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
On Tuesday, China's political leadership is convening at the Great Hall of the People in Beijing for the year's most significant event, known as the "Two Sessions." These closed-door meetings are the annual plenary sessions of both the National People's Congress and the Chinese People's Political Consultative Conference, typically held simultaneously in March. The sessions generally last for about ten days....